We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+2.88%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$51M
AUM Growth
-$64.6M
Cap. Flow
-$49.3M
Cap. Flow %
-96.64%
Top 10 Hldgs %
55.64%
Holding
66
New
2
Increased
14
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$3.42M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$827K
3
KYNB
Kyntra Bio
KYNB
+$730K
4
ALXN
Alexion Pharmaceuticals
ALXN
+$513K
5
TSRO
TESARO, Inc.
TSRO
+$418K

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$5.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$5.51M
3
MRK icon
Merck
MRK
+$4.71M
4
RXDX
Ignyta, Inc.
RXDX
+$4.55M
5
AZN icon
AstraZeneca
AZN
+$4.16M

Sector Composition

Rank Sector Weight
1 Healthcare 65.24%
2 Miscellaneous 34.76%
3 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KPTI icon
26
Karyopharm Therapeutics
KPTI
$36.3M
$671K 1.32%
3,333
-3,334
-50% -$665K
TSRO
27
DELISTED
TESARO, Inc.
TSRO
$657K 1.29%
11,500
+6,500
+130% +$418K
CKPT
28
DELISTED
Checkpoint Therapeutics
CKPT
$495K 0.97%
11,276
– –
AKBA icon
29
Akebia Therapeutics
AKBA
$264M
$477K 0.94%
50,004
+28,995
+138% +$406K
PRQR icon
30
ProQR Therapeutics
PRQR
$262M
$473K 0.93%
153,846
-153,846
-50% -$495K
PCRX icon
31
Pacira BioSciences
PCRX
$1.01B
$389K 0.76%
12,500
-12,500
-50% -$445K
RARE icon
32
Ultragenyx Pharmaceutical
RARE
$1.41B
$372K 0.73%
7,291
-1,181
-14% -$59.5K
ADMS
33
DELISTED
Adamas Pharmaceuticals
ADMS
$359K 0.7%
15,000
-15,000
-50% -$473K
AXSM icon
34
Axsome Therapeutics
AXSM
$11.6B
$327K 0.64%
133,500
– –
TECH icon
35
Bio-Techne
TECH
$11.3B
$303K 0.59%
8,036
+88
+1% +$3.11K
UTHR icon
36
United Therapeutics
UTHR
$21.3B
$290K 0.57%
2,579
+529
+26% +$67.2K
GRFS
37
Grifois
GRFS
$5.14B
$285K 0.56%
13,422
+1,857
+16% +$42.3K
IQV icon
38
IQVIA
IQV
$43.1B
$283K 0.56%
2,889
+474
+20% +$47.9K
PGEN icon
39
Precigen
PGEN
$2.45B
$283K 0.56%
18,478
+4,257
+30% +$60.9K
AVXS
40
DELISTED
AveXis, Inc. Common Stock
AVXS
$281K 0.55%
2,275
-225
-9% -$26.7K
CRL icon
41
Charles River Laboratories
CRL
$13.3B
$279K 0.55%
2,613
+459
+21% +$49.5K
ICPT
42
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$277K 0.54%
4,496
+717
+19% +$43.2K
GILD icon
43
Gilead Sciences
GILD
$182B
$276K 0.54%
3,667
+592
+19% +$47.1K
NBIX icon
44
Neurocrine Biosciences
NBIX
$16B
$268K 0.53%
3,232
-972
-23% -$82.1K
PRTK
45
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$260K 0.51%
20,000
-20,000
-50% -$298K
MDCO
46
DELISTED
Medicines Co
MDCO
$231K 0.45%
7,000
-7,000
-50% -$219K
BLUE
47
DELISTED
bluebird bio
BLUE
$226K 0.44%
+102
New +$259K
SCTL
48
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$139K 0.27%
14,066
-14,067
-50% -$118K
CFRX
49
DELISTED
ContraFect Corporation
CFRX
$122K 0.24%
94
-94
-50% -$116K
PGNX
50
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$81K 0.16%
10,891
-10,891
-50% -$72.4K
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q1 2018 Portfolio in Review

As of Q1 2018, Opus Point Partners Management held 66 positions worth $51M, down 56% from $116M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opus Point Partners Management withdrew a net $49.3M in Q1 2018, closing 15 positions and reducing 32 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $5.51M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 67% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Opus Point Partners Management opened a new position in bluebird bio worth $226K.

  • Opus Point Partners Management's largest Q1 2018 buy was bluebird bio: 102 shares worth $226K.
  • Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q1 2018, an estimated $3.42M increase.
  • Opus Point Partners Management's biggest Q1 2018 reduction was Nektar Therapeutics, cutting an estimated $5.9M.
  • Opus Point Partners Management fully exited Bristol-Myers Squibb in Q1 2018, selling an estimated $5.51M.
  • Opus Point Partners Management's ten largest holdings make up 56% of its $51M portfolio in Q1 2018.
  • Opus Point Partners Management opened 2 new positions and closed 15 in Q1 2018.
  • Opus Point Partners Management's portfolio value fell 56% quarter-over-quarter to $51M.

Based on Opus Point Partners Management's 13F filing for Q1 2018, filed 15 May 2018.